Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 19/20 | 0.74 |
| ▸ | JAK1 | P23458 | 9/20 | 0.74 |
| ▸ | TYK2 | P29597 | 9/20 | 0.74 |
| ▸ | JAK3 | P52333 | 9/20 | 0.74 |
| ▸ | BTK | Q06187 | 6/20 | 0.72 |
| ▸ | BRD4 | O60885 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15994351 | 0.88 | JAK2 (0.73) | JAK2JAK1TYK2JAK3BTK | |
| SCHEMBL140129 | 0.85 | JAK2 (1.00) | JAK2JAK1TYK2JAK3BTK | |
| SCHEMBL27997770 | 0.85 | JAK2 (0.80) | JAK2JAK1TYK2JAK3BTK | |
| SCHEMBL146089 | 0.85 | JAK2 (0.87) | JAK2JAK1TYK2JAK3BTK | |
| SCHEMBL146155 | 0.84 | JAK2 (1.00) | JAK2JAK1TYK2JAK3BTK | |
| SCHEMBL140896 | 0.83 | JAK2 (1.00) | JAK2JAK1TYK2JAK3BTK | |
| SCHEMBL141018 | 0.83 | JAK2 (0.82) | JAK2JAK1TYK2JAK3BTK | |
| SCHEMBL143045 | 0.82 | JAK2 (0.80) | JAK2JAK1TYK2JAK3BTK | |
| SCHEMBL141001 | 0.82 | JAK2 (0.77) | JAK2JAK1TYK2JAK3BTK | |
| SCHEMBL139899 | 0.82 | JAK2 (1.00) | JAK2JAK1TYK2JAK3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2961747-B1 | CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-15 | — | — | EP | disclosed |
| WO-2014134267-A1 | CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-04 | — | — | WO | disclosed |